Status:
UNKNOWN
Analysis of Circulating DNA in Blood Samples of Glioma-affected Patients
Lead Sponsor:
Corporacion Parc Tauli
Conditions:
Glioma
Circulating Tumor Cell
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The present pilot study aims to investigate a new strategy in the liquid biopsy protocol for the diagnosis of gliomas based on the detection of circulating tumor DNA in the blood of patients with brai...
Detailed Description
Currently, brain tumors are detected by means of an imaging technique (usually magnetic resonance imaging) with a contrast agent. The determination of the type of tumor, as well as its grading, is usu...
Eligibility Criteria
Inclusion
- Age ≥ 18 years.
- De novo primary brain lesion, compatible with a glioma according to contrast-enhanced magnetic resonance images. The injury must be treated by the usual surgical procedure.
- Signature of informed consent.
Exclusion
- Pregnant or breastfeeding women.
- Reasonable doubts in the diagnosis of glioma by magnetic resonance, or patients whose tissue biopsy diagnoses a brain lesion other than a glioma.
- Patients who cannot undergo surgical resection, or when the tissue samples taken are not significant enough to be analyzed.
- Inability or disagreement with signing the informed consent.
Key Trial Info
Start Date :
January 31 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 31 2024
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT05964153
Start Date
January 31 2023
End Date
January 31 2024
Last Update
August 30 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Universitari Parc Taulí
Sabadell, Barcelona, Spain, 08208